Study to Compare Pharmacokinetics and Safety of CT-P52 and US-licensed Taltz in Healthy Subjects
NCT07200986
·
clinicaltrials.gov ↗
PHASE1
Phase
ACTIVE_NOT_RECRUITING
Status
218
Enrollment
INDUSTRY
Sponsor class
Conditions
Healthy Participants
Interventions
BIOLOGICAL:
Ixekizumab
Sponsor
Celltrion